Skip to main content
TipRanks
Go Ultimate75% OFF

Traws Pharma (TRAW) Stock Price & Analysis

1,879 Followers

TRAW Stock Chart & Stats

$0.23-$0.03(-10.38%)
At close: 4:00 PM EST
$0.2$0.4$0.6Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.23 - $0.28
52-Week Range
$0.22 - $3.23
Previous Close
$0.26
Volume
N/A
Average Volume (3M)
199.43K
Market Cap
$3.59M
Enterprise Value
$8.37M
Total Cash (Recent Filing)
$3.13M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.79
Next Earnings
Mar 18, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Ratutrelvir Clinical Progress

Phase 2a results show ratutrelvir achieved symptom resolution comparable to PAXLOVID, fewer treatment-related adverse events, and no rebound through Day 28. This supports a differentiated clinical profile, particularly for patients unable to use ritonavir, and advances the lead program toward later development.

TXM Formulation And Safety Progress

Comparable exposure and tolerability for the compressed TXM tablet support development of a more practical formulation, while the reported toxicology findings reduce a key preclinical hurdle. Together, these results strengthen the feasibility of the once-monthly influenza program and its continued advancement.

Flexible Development Funding

The equity facility gives Traws a defined source of capital for pipeline development, working capital, and general corporate needs over as long as 36 months. That flexibility can help maintain clinical execution despite limited internal cash generation and reduce dependence on immediate financing decisions.

Bears Say

Persistent Cash Burn

Consistently negative operating and free cash flow indicates that the company is not yet funding operations internally. The sharp 2025 deterioration increases reliance on external capital, constrains strategic flexibility, and could force financing activity before the pipeline produces commercial cash inflows.

Negative Equity And Weak Financial Flexibility

Negative equity means accumulated losses or write-downs have overwhelmed the capital base, even without reported debt. This weakens financial resilience, limits flexibility in funding research and development, and may make future capital raising more important as programs progress.

Unproven Core Earnings Quality

The apparent 2025 improvement in revenue and net income does not reflect stronger operating performance because EBITDA and EBIT remained deeply negative. This makes earnings difficult to sustain, leaves the business dependent on pipeline success, and limits confidence in near-term profitability.

Traws Pharma News

TRAW FAQ

What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.22 and its highest was $3.23 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $3.59M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s next earnings report is estimated for Mar 18, 2027 (not yet confirmed), which is in 120 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Nov 16, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.025.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.11.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,368,277 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -10.385%.
Which hedge fund is a major shareholder of Traws Pharma?
Hedge funds hold Traws Pharma shares: the largest hedge-fund position in Traws Pharma is 72,328,723 shares, and hedge funds decreased their holdings by 15.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology